This study was a randomised, double blind, placebo controlled trial conducted in five hospitals in China to assess the effects of low dose esketamine on postpartum depression. Pregnant individuals with Edinburgh postnatal depression scale scores of ≥10 were enrolled and administered either esketamine or a placebo. The primary endpoint was the prevalence of major depressive episodes at 42 days postpartum. Secondary endpoints included depression scores, pain intensity, breastfeeding rates, hospital stay length, and complications. Adverse events were continuously monitored. Results were analysed using statistical tests, with subgroup analyses performed to evaluate treatment interactions. Missing data were not replaced, and statistical significance was set at P <0.05.
Source link
Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial
